Drug details

Fluorodopa FDOPA (f18 injection)

type of

Fluorodopa (F18 injection) is a radioactive diagnostic agent used in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa is an adjunct to other diagnostic evaluations.

This drug may have the following side effects:

• injection site pain

The following drugs are related to Fluorodopa FDOPA, either as a replacement or used together:

• Osmolex ER (amantadine)
• Gocovri (amantadine extended release capsules, for oral use)
• Apokyn (apomorphine)
• Azilect (rasagiline)
• Cogentin (benztropine mesylate injection)
• Parlodel (bromocriptine mesylate)
• Rytary (carbidopa and levodopa capsules)
• Duopa (carbidopa and levodopa enteral suspension)
• Parcopa (carbidopa and levodopa extended-release tablets)
• Stalevo (carbidopa, levodopa and entacapone)
• Sinemet (carbidopa-levodopa)
• Sinemet CR (carbidopa-levodopa sustained release)
• Comtan (entacapone)
• Eldepryl (selegiline hcl)
• Exelon (rivastigmine tartrate)
• Exelon Patch (rivastigmine transdermal system)
• Nourianz (istradefylline tablets)
• Mirapex (pramipexole)
• Mirapex ER (pramipexole dihydrochloride extended-release tablets)
• Neupro (rotigotine transdermal system)
• Requip (ropinirole hcl)
• Requip XL (ropinirole extended release tablets)
• Xadago (safinamide tablets)
• Zelapar (selegiline hydrochloride)
• Tasmar (tolcapone)